Sabra Health Care REIT A Buy, As Q1 Results Show Portfolio Growth
Sabra Health Care REIT (SBRA) is considered a buy based on its Q1 results showing portfolio and net operating income growth, along with a reasonable valuation and 5.6% dividend yield. The company benefits from geographic diversification and strong revenue performance, though EBITDA margins are declining. Persistent challenges include rising labor costs and shifting trends in home care services.
- ▪Sabra Health Care REIT reported portfolio and NOI growth in Q1 2026, supporting a buy rating.
- ▪The REIT offers a 5.6% dividend yield but faces pressure from declining EBITDA margins and flat long-term dividend growth.
- ▪Labor cost inflation and evolving home care demand are key risks to SBRA's future performance.
- ▪SBRA is fairly valued with strong geographic diversification across its healthcare property portfolio.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Stock Ideas","item":"https://seekingalpha.com/stock-ideas"},{"@type":"ListItem","position":3,"name":"Long Ideas","item":"https://seekingalpha.com/stock-ideas/long-ideas"},{"@type":"ListItem","position":4,"name":"Real Estate Analysis","item":"https://seekingalpha.com/stock-ideas/real-estate"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4905798-sabra-health-care-reit-a-buy-as-q1-results-show-portfolio-growth"},"author":{"@type":"Person","name":"Albert…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
